Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.38 |
| ▸ | NCK1 | P16333 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24506894 | 0.86 | BACE1 (0.38) | BACE1NCK1NOS2NOS3KDM4E | |
| SCHEMBL4045372 | 0.77 | PLAU (0.43) | BACE1NCK1NOS2PLAUNCF1 | |
| SCHEMBL25449339 | 0.76 | ALDH1A1 (0.35) | ALDH1A1HSD17B10 | |
| SCHEMBL25106981 | 0.76 | BACE1 (0.41) | BACE1NCK1NOS2NOS3KDM4E | |
| SCHEMBL25449327 | 0.73 | ALDH1A1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL26795843 | 0.71 | — | — | |
| SCHEMBL1551266 | 0.71 | TLR9 (0.42) | KDM4EALDH1A1KMT2AHSD17B10PLAU | |
| SCHEMBL27152551 | 0.70 | — | — | |
| SCHEMBL22521384 | 0.69 | KDM4E (0.43) | BACE1NCK1NOS2NOS3KDM4E | |
| SCHEMBL25449340 | 0.69 | NOS3 (0.36) | NOS2NOS3KDM4EHSD17B10NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | BACE1 4154/4885NCK1 1666/4885NOS2 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.